Diligence memo · auto-generated · as of July 2, 2026

Vektor Medical, Inc.

Vektor Medical, Inc. looks fair against its niche peers and is at-risk on financing cadence.

WatchOverdue for a raise versus sector cadence — could be a bridge, a down round, or distress. Watch for the next filing.

Businessfiled

Vektor Medical, Inc. operates in Biotechnology, based in San Diego.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Vektor Medical, Inc. has raised $33M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).

Largest single filing: $29M on 2024-02-02.

Most recent recorded round closed around 2024-02-02.

Valuation (modeled)modeled

Provath models Vektor Medical, Inc. at approximately $246M (range $58M–$476M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.47× the median modeled value of Series B Biotechnology companies in 2022–2024 (197 peers) — value vs value, same stage and era. Within the normal band (147% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 36 months.

Last raise 2.4 yr ago; this sector typically re-raises about every 14 months.

Past due for a raise versus sector cadence — watch for distress or a bridge.

The last round stepped up 8.0× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 76% of Biotechnology peers (4293 compared).

Modeled value ranks above 74% of those peers.

Closest niche peers: Mt McKinley Medical Holding Corp USA, YAP Therapeutics Inc, Pinteon Therapeutics, Inc., OncXerna Therapeutics, Ltd., EpiBiologics, Inc..

Peoplefiled

12 named people on file across officers, directors and signatories.

Risks & flagsmixed

Overdue for a raise versus sector norm — distress or bridge risk.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.